

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6322116

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOPHARMAWORKS LLC	07/29/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CYBREXA 3, INC.
<b>Street Address:</b>	5 SCIENCE PARK
<b>Internal Address:</b>	395 WINCHESTER AVENUE
<b>City:</b>	NEW HAVEN
<b>State/Country:</b>	CONNECTICUT
<b>Postal Code:</b>	06511
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16924445
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	+1 (212) 641-2296
<b>Email:</b>	APSI@fr.com
<b>Correspondent Name:</b>	JUSTIN E. SEARS
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	43236-0008001
<b>NAME OF SUBMITTER:</b>	LAUREN COLICCHIO
<b>SIGNATURE:</b>	/Lauren Colicchio/
<b>DATE SIGNED:</b>	09/28/2020
<b>Total Attachments: 4</b>	
source=43236-0008001 Assignment from Biopharmaworks LLC to Cybrella 3 Inc#page1.tif	
source=43236-0008001 Assignment from Biopharmaworks LLC to Cybrella 3 Inc#page2.tif	
source=43236-0008001 Assignment from Biopharmaworks LLC to Cybrella 3 Inc#page3.tif	
source=43236-0008001 Assignment from Biopharmaworks LLC to Cybrella 3 Inc#page4.tif	

ASSIGNMENT

Assignor: BioPharmaWorks LLC  
a corporation organized and existing under the laws of Connecticut, and having a  
place of business at:  
93 Shennecossett Road  
Groton, CT 06340

Assignee: Cybrexa 3, Inc.  
a corporation organized and existing under the laws of  
Connecticut, and having a place of business at:  
5 Science Park  
395 Winchester Avenue  
New Haven, CT 06511

Country	Application No.	Filing Date	Title
United States	16/924,445	7/9/2020	PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS
WIPO	PCT/US2020/041348	7/9/2020	PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby executes this Assignment.

Assignor: BioPharmaWorks LLC

Signature: Robert G. Volkman

Date: 7/29/2020

Name: ROBERT A. VOLKMAN

Title: CSO

Witnessed by:


Signature: Jotham W. Coe

Date: 7/29/2020

Print Name: Jotham W. Coe

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Cybrea 3, Inc.


Signature:  \_\_\_\_\_

Date: 8-24-20

Name: Per Hellstrand

Title: CEO

Witnessed by:

Signature:  \_\_\_\_\_

Date: 8/24/20

Print Name: Lisa Behm

24039245.doc